Banani
: Vaxart Positioned to Further Advance Oral COVID-19
Vaxart Positioned to Further Advance Oral COVID-19 Vaccine; Analyst Says ‘Buy’
... Who is emerging as a likely winner? If you ask 5-star analyst Vernon Bernardino, of H.C. Wainwright, of the 165-plus vaccine candidates (38 in clinical-stage testing) in development, Vaxart’s (VXRT) chances are looking pretty good...
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
Key Findings:
Immunization with the vaccine candidate induced IgA response in the lungs of animals, which is indicative of a mucosal immune response. Of particular note, neutralizing antibodies in the lungs were observed at a very high percentage of the total antibody response.
Immunization with our vaccine candidate expressing full length S and N proteins induced IgG responses in a dose-dependent manner.
Antigen-specific CD4+ and CD8+ T cells were induced at both low and high doses.
Vaccine administration induced only low levels of IL-4 production, suggesting little risk of vaccine- dependent disease enhancement.
Ideale Trader- Aktie . Zwischen 13.00 Uhr und 15.00 Uhr gibt es , wenn überhaupt , einen Anstieg . Danach nur noch eine Richtung . Heute im Hoch : 14.15 Uhr = 5,400/5,700€ . Jetzt : 19.45 Uhr = 4,240/4,360€ ( Differenz : 21,50% ).... nur zum Traden das Teil . Das Tief dann morgen früh .. denn es fällt weiter , keine Käufer ! Genau so denken und handeln die Amis und nur so gehts .
Wenn es keinen Haken geben würde , gäbe es nicht diese Schwankungen . Das ist FAKT ! ( Die Amerikaner sind noch nicht gänzlich überzeugt ) Was ist wenn es keine staatlichen Mittel gibt ? Was dann ... ? Ich bin überzeugt von Vaxart und seinen Produkten , aber ich setzte nichts voraus .
Dinobutcher
: Recruitment for Phase 1 clinical study expected to
start end of september. und das dauert natürlich erstmal, wenn man sieht, was die potentiellen Kanditaten nicht alles haben dürfen, bzw haben müssen. Criteria Inclusion Criteria: 1. Male or female between the ages of 18 to 54 years, inclusive. 2. Negative for SARS-CoV-2 infection at the time of screening 3. In generally good health, without significant medical illness 4. Demonstrates comprehension of the protocol procedures and is able to provide written informed consent. 5. Available for all planned visits and willing to complete all protocol defined procedures and assessments 6. Body mass index between 17 and 30 kg/m2 at screening. 7. Female subjects must have a negative pregnancy test at screening and before each vaccination and fulfill an acceptable method of birth control (per protocol)
Exclusion Criteria: 1. Known previous exposure to SARS-CoV-2 or receipt of an investigational product for the prevention or treatment of COVID-19, middle east respiratory syndrome (MERS), or severe acute respiratory syndrome (SARS). 2. Is in a current occupation with high risk of exposure to SARS-CoV-2 3. Individuals with the following underlying medical conditions who are at higher risk (or might be at higher risk) of severe illness from COVID-19 per the CDC's guidance 4. Donation or use of blood or blood products within 4 weeks prior to vaccination or planned donation during the study period. 5. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic. 6. Any condition that resulted in the absence or removal of the spleen. 7. Positive HIV, HBsAg or HCV tests at the screening visit. 24.9.2020 Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults - Full Text View - Clin… https://clinicaltrials.gov/ct2/show/...m=vaxart&draw=2&rank=1 6/8 8. Stool sample with occult blood at screening. 9. Use of antiviral medications, including anti-retrovirals, or any prescriptive medications for the prevention of COVID-19 within 7 days before vaccination 10. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids or medications known to affect the immune function within 7 to 14 days before vaccination 11. Regular use of nonsteroidal anti-inflammatory drugs, sulfonylureas, and angiotensin II blockers within 7 days before vaccination 12. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness 13. History of drug, alcohol or chemical abuse within 1 year of screening or positive urine drug screen for drugs of abuse at screening 14. History of hypersensitivity or allergic reaction to any component of the investigational vaccine 15. Administration of any investigational vaccine, drug or device within 8 weeks preceding vaccination 16. Any other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a subject participating in the trial, would render the subject unable to comply with the protocol or would interfere with the evaluation of the study endpoints. Contacts and Locations Information from the National Library of Medicine United States, California 24.9.2020 Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults
Upcoming Key Milestones 1. Week of Oct 12...FPFV Weds Oct 14 Based on what is posted on the website of WCCT Global (the company running the Phase 1 trial) screening of patients has been ongoing since mid September and the FPFV (first dosing of the first patient) should be this on Weds Oct 14! Two (2) pill vaccine doses are being evaluated in the Study. There are 48 subjects being recruited into 2 Groups with +/- 24 subjects per group. Group 1 has 3 cohorts of +/- 8 subjects each and Group 2 has 2 cohorts of +/- 12 subjects each. It appears to me that All subjects are dosed on Day 1 and get a repeat dose on Day 29. Patients return weekly back to the clinic as outpatients for various clinical assessments. 2. Week of Oct 19 Results of hamster challenge study. In the sept 14 company press release the CSO stated mid Oct for results 3. Week of Oct 26 Results from NHP (monkey) study I seem to recall a comment in one of the presentations from either the CEO or CSO about results by the end of Oct. it will be a very exciting few weeks ahead. It would be even better if these animal results are favorable leading to Govt Funding.
Based on a review of the last quarterly report, the company has significant cash on hand (tens of millions of dollars) to complete Phase 2 and 3 Trials on their own but having a partner like US Govt could significantly speed up development and, more importantly reduce the financial “risk”.
hat den amis heute nicht gereicht , 10% Abverkauf. Übernächste Woche kommen Ergebnisse der Primaten study, hoffentlich werden sie dann mehr beeindruckt. Das Beste wäre natürlich, wenn sie die Pillen von dem großen Orange Hamster in Washington testen lassen.